VIVERA
Vivera Pharmaceuticals
Application Filed: 2018-01-03
Trademark Application Details
ABANDONED-FAILURE TO RESPOND OR LATE RESPONSE
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87741801 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Brian A. Hall |
| Law Office Assigned | L80 |
| Employee Name | BEN, LINDSEY HEATHER |
Timeline
| 2018-01-03 | Application Filed |
| 2019-04-23 | Abandon |
| 2019-05-20 | Location: TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED |
| 2019-05-20 | Status: Dead/Abandoned |
| 2019-05-20 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Vivera Pharmaceuticals |
| Address | 17809 Gillette Avenue Irvine NV 92614 |
| Legal Entity Type | Corporation |
| Legal Entity State | NV |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of orodispersable tablets and/or sublingual tablets that facilitate the delivery of pharmaceutical preparations; Nutraceuticals for use as a dietary supplement; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of the cardiovascular system, the circulatory system, the digestive system, the excretory system, the endocrine system, the integumentary system, the exocrine system, the lymphatic system, the immune system, the muscular system, the nervous system, the renal system, the urinary system, the reproductive system, and/or the skeletal system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Cardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of the endocannabinoid; Human vaccine preparations; Oral vaccine preparations |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2018-01-06 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-01-18 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2018-01-29 | 3 DOCK D:Assigned to Examiner |
| ASSIGNED TO EXAMINER | 2018-10-16 | 4 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2018-10-22 | 5 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2018-10-22 | 6 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2018-10-22 | 7 GNRN O:Outgoing Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2019-04-22 | 8 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2019-04-22 | 9 ARAA I:Incoming Correspondence |
| ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | 2019-05-20 | 10 ABN2 O:Outgoing Correspondence |
| ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | 2019-05-20 | 11 MAB2 E:E-Mail |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 